These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 38599309)

  • 1. APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1.
    Liu Y; Li N; Guo Y; Zhou Q; Yang Y; Lu J; Tian Z; Zhou J; Yan S; Li X; Shi L; Jiang S; Ge J; Feng R; Huang D; Zeng Z; Fan S; Xiong W; Li G; Zhang W
    Int Immunopharmacol; 2024 Aug; 137():112523. PubMed ID: 38909500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.
    Ding D; Liang R; Li T; Lan T; Li Y; Huang S; He G; Ren J; Li W; Zheng Z; Chen T; Fang J; Huang L; Shuai X; Wei B
    J Control Release; 2024 May; 369():309-324. PubMed ID: 38554771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
    Altves S; Guclu E; Yetisgin E; Bilecen K; Vural H
    World J Microbiol Biotechnol; 2024 May; 40(7):204. PubMed ID: 38755413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
    Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
    ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression downregulation by RNF43 in gastric carcinoma enhances antitumour activity of T cells.
    Yang J; Wei M; Liu X; Shao X; Yan J; Liu J; Wen J; Zhang X; Dong R; Min M
    Scand J Immunol; 2023 Jun; 97(6):e13268. PubMed ID: 39007965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARα phosphorylation regulates colorectal tumor immune escape.
    Gou Q; Tian X; Dong C; Yan B; Chen M; Shi J; Yang L; Hou Y
    J Biol Chem; 2024 Jun; 300(7):107447. PubMed ID: 38844134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Nuclear Receptor Coactivator SRC-1 Prevents Colorectal Cancer Immune Escape by Reducing Transcription and Protein Stability of PD-L1.
    Hong Y; Chen Q; Wang Z; Zhang Y; Li B; Guo H; Huang C; Kong X; Mo P; Xiao N; Xu J; Ye Y; Yu C
    Adv Sci (Weinh); 2024 Jul; ():e2310037. PubMed ID: 38953362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin αvβ6 mediates the immune escape through regulation of PD-L1 and serves as a novel marker for immunotherapy of colon carcinoma.
    Yu J; E T; Zhou M; Niu J; Wang J; Miao R; Dong C; Gao H; Jing C; Liang B
    Am J Cancer Res; 2024; 14(5):2608-2625. PubMed ID: 38859847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci.
    Miliotis C; Ma Y; Katopodi XL; Karagkouni D; Kanata E; Mattioli K; Kalavros N; Pita-Juárez YH; Batalini F; Ramnarine VR; Nanda S; Slack FJ; Vlachos IS
    Nat Commun; 2024 May; 15(1):4319. PubMed ID: 38773080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
    Wu Y; Chen W; Xu ZP; Gu W
    Front Immunol; 2019; 10():2022. PubMed ID: 31507611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
    Ayala-Mar S; Donoso-Quezada J; González-Valdez J
    J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression.
    Khan B; Chen M; Wang H; Khan A; Hussain S; Shi J; Yang L; Hou Y
    Eur J Pharmacol; 2024 Jun; 972():176565. PubMed ID: 38599309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
    Shi Y; Fu Y; Zhang X; Zhao G; Yao Y; Guo Y; Ma G; Bai S; Li H
    Cancer Immunol Immunother; 2021 Jan; 70(1):61-73. PubMed ID: 32632663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy.
    Liang Y; Luo H; Li X; Liu S; Habib A; Liu B; Huang J; Wang J; Yi H; Hu B; Zheng L; Xie J; Zhu N
    Front Immunol; 2024; 15():1367040. PubMed ID: 38745661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extracts of
    Chang HL; Kuo YH; Wu LH; Chang CM; Cheng KJ; Tyan YC; Lee CH
    Int J Med Sci; 2020; 17(7):939-945. PubMed ID: 32308547
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.